The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Martin Filipits(University of Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Peter Regitnig(Medical University of Graz), Stefan Halper(Fachhochschule Wiener Neustadt), Richard Greil(Paracelsus Medical University), Tony Loughman(EKF Diagnostics (United States)), Daniel Egle(Innsbruck Medical University), Wolfgang Hulla(Fachhochschule Wiener Neustadt), Margaretha Rudas(Comprehensive Cancer Center Vienna), Stephen Barron(Broadcom (Ireland)), Marija Balić(University of Pittsburgh), Verena Kainz(Comprehensive Cancer Center Vienna), Des O'Leary(Broadcom (Ireland)), William M. Gallagher(University College Dublin)
Cited by 3
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k